LB002 safety and tolerability of arimoclomol in patients with sporadic inclusion body myositis: a randomised, double-blind, placebo-contolled, phase IIa proof-of-concept trial - Machado, P; Miller, A; herbelin, L (Ann Rheum Dis, 2013)
et al.